Evidence map›Paper›PMID 29968168›Full record

ReviewInternational journal of clinical oncology2018

Clinical outcomes of brain metastases from hepatocellular carcinoma: a multicenter retrospective study and a literature review.

Takeshi Okuda, Nakamasa Hayashi, Masamichi Takahashi, Takeo Uzuka, Yoshiko Okita, Ryohei Otani, Toshiyuki Fujinaka, Mitsugu Fujita, Amami Kato, Yoshitaka Narita and 1 more

Abstract readMulticenter StudyReview
PubMed Publisher
In one paragraph

Review in International journal of clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Takeshi OkudaDepartment of Neurosurgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan. okuda@med.kindai.ac.jp.ORCID http://orcid.org/0000-0001-8055-9434
Nakamasa HayashiDivision of Neurosurgery, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan.
Masamichi TakahashiDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center, Chuo-ku, Tokyo, Japan.
Takeo UzukaDepartment of Neurosurgery, Dokkyo Medical University, Shimotsuga-gun, Tochigi, Japan.
Yoshiko OkitaDepartment of Neurosurgery, Osaka National Hospital, Osaka, Osaka, Japan.
Ryohei OtaniDepartment of Neurosurgery, Dokkyo Medical University, Shimotsuga-gun, Tochigi, Japan.
Toshiyuki FujinakaDepartment of Neurosurgery, Osaka National Hospital, Osaka, Osaka, Japan.
Mitsugu FujitaDepartment of Microbiology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
Amami KatoDepartment of Neurosurgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan.
Yoshitaka NaritaDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center, Chuo-ku, Tokyo, Japan.
Yoko NakasuDivision of Neurosurgery, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe introduction of systemic chemotherapy for advanced hepatocellular carcinoma in recent years has led to the prediction that cases of brain metastases from hepatocellular carcinoma will increase. However, because brain metastases from hepatocellular carcinoma are relatively rare, the characteristics of this pathology are poorly understood.

methodsWe carried out a multicenter retrospective study to verify the characteristics of brain metastases from hepatocellular carcinoma in Japan.

resultsA total of 38 patients were enrolled and patient characteristics were poor general condition in many patients due to the progression of primary cancers. Stereotactic radiosurgery/stereotactic radiotherapy alone was the most common treatment (39.5%), with best supportive care provided for 10.5%. Median survival was 6 months, the neurological death rate was 28%, and the rate of brain hemorrhage was high (39.5%). Overall survival was analyzed for correlations with age, etiology of chronic liver disease, albumin-bilirubin (ALBI) grade, RPA classification, control of the primary tumor, number of brain metastases, brain hemorrhage, surgical resection, and radiotherapy. In multivariate analysis, ALBI grade, number of brain metastases and brain hemorrhage showed statistically significant correlation.

conclusionsA multivariate analysis extracted three items-ALBI grade, number of brain metastases, and brain hemorrhage-as prognostic factors for survival of brain metastases from hepatocellular carcinoma.

Indexed as

AdultAgedAged, 80 and overBrain NeoplasmsCarcinoma, HepatocellularDisease ProgressionFemaleHumansLiver NeoplasmsMaleMiddle AgedRadiosurgeryRetrospective StudiesSurvival RateTreatment OutcomeALBI gradeBrain metastasesHepatocellular carcinoma

Identifiers

PMID29968168

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.